Literature DB >> 33241859

Lassa hemorrhagic shock syndrome-on-a-chip.

Huaqi Tang1, Yasmine Abouleila1, Alireza Mashaghi1.   

Abstract

Lack of experimental human models hinders research on Lassa hemorrhagic fever and the development of treatment strategies. Here, we report the first chip-based model for Lassa hemorrhagic syndrome. The chip features a microvessel interfacing collagen network as a simple mimic for extracellular matrix, allowing for quantitative and real-time vascular integrity assessment. Luminal infusion of Lassa virus-like particles led to a dramatic increase in vascular permeability in a viral load-dependent manner. Using this platform, we showed that Fibrin-derived peptide FX06 can be used to suppress the vascular integrity loss. This simple chip-based model proved promising in the assessment of disease severity and provides an easy-to-use platform for future investigation of Lassa pathogenesis and drug development in a human-like setting.
© 2020 The Authors. Biotechnology and Bioengineering Published by Wiley Periodicals LLC.

Entities:  

Keywords:  Lassa hemorrhagic fever; Organ Chips; drug; microvessel; vascular permeability

Mesh:

Year:  2020        PMID: 33241859      PMCID: PMC7983903          DOI: 10.1002/bit.27636

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  20 in total

1.  Microfluidic organs-on-chips.

Authors:  Sangeeta N Bhatia; Donald E Ingber
Journal:  Nat Biotechnol       Date:  2014-08       Impact factor: 54.908

2.  Type I interferon is a therapeutic target for virus-induced lethal vascular damage.

Authors:  Roberto Baccala; Megan J Welch; Rosana Gonzalez-Quintial; Kevin B Walsh; John R Teijaro; Anthony Nguyen; Cherie T Ng; Brian M Sullivan; Alessandro Zarpellon; Zaverio M Ruggeri; Juan Carlos de la Torre; Argyrios N Theofilopoulos; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2014-06-02       Impact factor: 11.205

3.  Lassa virus circulating in Liberia: a retrospective genomic characterisation.

Authors:  Michael R Wiley; Lawrence Fakoli; Andrew G Letizia; Stephen R Welch; Jason T Ladner; Karla Prieto; Daniel Reyes; Nicole Espy; Joseph A Chitty; Catherine B Pratt; Nicholas Di Paola; Fahn Taweh; Desmond Williams; Jon Saindon; William G Davis; Ketan Patel; Mitchell Holland; Daniel Negrón; Ute Ströher; Stuart T Nichol; Shanmuga Sozhamannan; Pierre E Rollin; John Dogba; Tolbert Nyenswah; Fatorma Bolay; César G Albariño; Mosoka Fallah; Gustavo Palacios
Journal:  Lancet Infect Dis       Date:  2019-10-03       Impact factor: 25.071

4.  Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever.

Authors:  Chad E Mire; Robert W Cross; Joan B Geisbert; Viktoriya Borisevich; Krystle N Agans; Daniel J Deer; Megan L Heinrich; Megan M Rowland; Augustine Goba; Mambu Momoh; Mathew L Boisen; Donald S Grant; Mohamed Fullah; Sheik Humarr Khan; Karla A Fenton; James E Robinson; Luis M Branco; Robert F Garry; Thomas W Geisbert
Journal:  Nat Med       Date:  2017-09-04       Impact factor: 53.440

Review 5.  Of mice and not men: differences between mouse and human immunology.

Authors:  Javier Mestas; Christopher C W Hughes
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

6.  Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: a retrospective, observational cohort study.

Authors:  Peter Okokhere; Andres Colubri; Chukwuemeka Azubike; Christopher Iruolagbe; Omoregie Osazuwa; Shervin Tabrizi; Elizabeth Chin; Sara Asad; Ehi Ediale; Mojeed Rafiu; Donatus Adomeh; Ikponmwosa Odia; Rebecca Atafo; Chris Aire; Sylvanus Okogbenin; Meike Pahlman; Beate Becker-Ziaja; Danny Asogun; Terrence Fradet; Ben Fry; Stephen F Schaffner; Christian Happi; George Akpede; Stephan Günther; Pardis C Sabeti
Journal:  Lancet Infect Dis       Date:  2018-03-06       Impact factor: 25.071

7.  Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.

Authors:  Luis M Branco; Jessica N Grove; Frederick J Geske; Matt L Boisen; Ivana J Muncy; Susan A Magliato; Lee A Henderson; Randal J Schoepp; Kathleen A Cashman; Lisa E Hensley; Robert F Garry
Journal:  Virol J       Date:  2010-10-20       Impact factor: 4.099

8.  Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits.

Authors:  James E Robinson; Kathryn M Hastie; Robert W Cross; Rachael E Yenni; Deborah H Elliott; Julie A Rouelle; Chandrika B Kannadka; Ashley A Smira; Courtney E Garry; Benjamin T Bradley; Haini Yu; Jeffrey G Shaffer; Matt L Boisen; Jessica N Hartnett; Michelle A Zandonatti; Megan M Rowland; Megan L Heinrich; Luis Martínez-Sobrido; Benson Cheng; Juan C de la Torre; Kristian G Andersen; Augustine Goba; Mambu Momoh; Mohamed Fullah; Michael Gbakie; Lansana Kanneh; Veronica J Koroma; Richard Fonnie; Simbirie C Jalloh; Brima Kargbo; Mohamed A Vandi; Momoh Gbetuwa; Odia Ikponmwosa; Danny A Asogun; Peter O Okokhere; Onikepe A Follarin; John S Schieffelin; Kelly R Pitts; Joan B Geisbert; Peter C Kulakoski; Russell B Wilson; Christian T Happi; Pardis C Sabeti; Sahr M Gevao; S Humarr Khan; Donald S Grant; Thomas W Geisbert; Erica Ollmann Saphire; Luis M Branco; Robert F Garry
Journal:  Nat Commun       Date:  2016-05-10       Impact factor: 14.919

9.  Mature induced-pluripotent-stem-cell-derived human podocytes reconstitute kidney glomerular-capillary-wall function on a chip.

Authors:  Samira Musah; Akiko Mammoto; Thomas C Ferrante; Sauveur S F Jeanty; Mariko Hirano-Kobayashi; Tadanori Mammoto; Kristen Roberts; Seyoon Chung; Richard Novak; Miles Ingram; Tohid Fatanat-Didar; Sandeep Koshy; James C Weaver; George M Church; Donald E Ingber
Journal:  Nat Biomed Eng       Date:  2017-05-10       Impact factor: 25.671

10.  Genomic Analysis of Lassa Virus during an Increase in Cases in Nigeria in 2018.

Authors:  Katherine J Siddle; Philomena Eromon; Kayla G Barnes; Samar Mehta; Judith U Oguzie; Ikponmwosa Odia; Stephen F Schaffner; Sarah M Winnicki; Rickey R Shah; James Qu; Shirlee Wohl; Patrick Brehio; Christopher Iruolagbe; John Aiyepada; Eghosa Uyigue; Patience Akhilomen; Grace Okonofua; Simon Ye; Tolulope Kayode; Fehintola Ajogbasile; Jessica Uwanibe; Amy Gaye; Mambu Momoh; Bridget Chak; Dylan Kotliar; Amber Carter; Adrianne Gladden-Young; Catherine A Freije; Omigie Omoregie; Blessing Osiemi; Ekene B Muoebonam; Michael Airende; Rachael Enigbe; Benevolence Ebo; Iguosadolo Nosamiefan; Paul Oluniyi; Mahan Nekoui; Ephraim Ogbaini-Emovon; Robert F Garry; Kristian G Andersen; Daniel J Park; Nathan L Yozwiak; George Akpede; Chikwe Ihekweazu; Oyewale Tomori; Sylvanus Okogbenin; Onikepe A Folarin; Peter O Okokhere; Bronwyn L MacInnis; Pardis C Sabeti; Christian T Happi
Journal:  N Engl J Med       Date:  2018-10-17       Impact factor: 91.245

View more
  2 in total

1.  Lassa hemorrhagic shock syndrome-on-a-chip.

Authors:  Huaqi Tang; Yasmine Abouleila; Alireza Mashaghi
Journal:  Biotechnol Bioeng       Date:  2020-12-04       Impact factor: 4.530

2.  Infection of Human Endothelial Cells with Lassa Virus Induces Early but Transient Activation and Low Type I IFN Response Compared to the Closely-Related Nonpathogenic Mopeia Virus.

Authors:  Othmann Merabet; Natalia Pietrosemoli; Emeline Perthame; Jean Armengaud; Jean-Charles Gaillard; Virginie Borges-Cardoso; Maïlys Daniau; Catherine Legras-Lachuer; Xavier Carnec; Sylvain Baize
Journal:  Viruses       Date:  2022-03-21       Impact factor: 5.048

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.